MAPT and Alzheimer disease: We note several exciting extensions to complement our research directions—including testing if predicting a combination of amyloid and tau (e.g., the ratio of these biomarkers) yields better performance as suggested previously (de la Torre et al. 2010) and longitudinal assessment of trends to check if proxy‐markers can offer an earlier AD risk assessment compared to MRI data.